BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 33121914)

  • 21. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
    Preisser F; Bandini M; Marchioni M; Nazzani S; Tian Z; Pompe RS; Fossati N; Briganti A; Saad F; Shariat SF; Heinzer H; Huland H; Graefen M; Tilki D; Karakiewicz PI
    Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolated seminal vesicle invasion imparts better outcomes after radical retropubic prostatectomy for clinically localized prostate cancer: prognostic stratification of pt3b disease by nodal and margin status.
    Masterson TA; Pettus JA; Middleton RG; Stephenson RA
    Urology; 2005 Jul; 66(1):152-5. PubMed ID: 15992904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Outcome after radical prostatectomy with extended pelvic lymphadenectomy for untreated high-risk clinically localized prostate cancer].
    Tsurusaki T; Yamasaki Y; Maruta S
    Nihon Hinyokika Gakkai Zasshi; 2013 May; 104(3):496-504. PubMed ID: 23819361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and Validation of an Improved Pathological Nodal Staging System in Men with Prostate Cancer.
    Daskivich TJ; Luu M; Freedland SJ; Sandler H; Spratt DE; Zumsteg ZS
    J Urol; 2022 Mar; 207(3):581-591. PubMed ID: 34694160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup.
    Moschini M; Sharma V; Zattoni F; Boorjian SA; Frank I; Gettman MT; Thompson RH; Tollefson MK; Kwon ED; Karnes RJ
    J Urol; 2016 Jun; 195(6):1773-8. PubMed ID: 26723866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
    Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
    Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience.
    Pierorazio PM; Gorin MA; Ross AE; Feng Z; Trock BJ; Schaeffer EM; Han M; Epstein JI; Partin AW; Walsh PC; Bivalacqua TJ
    Prostate; 2013 Nov; 73(15):1673-80. PubMed ID: 24019101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer?
    Sivaraman A; Benfante N; Touijer K; Coleman J; Scardino P; Laudone V; Eastham J
    Investig Clin Urol; 2018 Mar; 59(2):83-90. PubMed ID: 29520383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
    Moschini M; Sharma V; Zattoni F; Quevedo JF; Davis BJ; Kwon E; Karnes RJ
    Eur Urol; 2016 Jan; 69(1):135-42. PubMed ID: 25865061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer.
    Washington SL; Cowan JE; Herlemann A; Zuniga KB; Masic S; Nguyen HG; Carroll PR
    Prostate; 2021 Feb; 81(2):102-108. PubMed ID: 33075151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
    Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
    Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Robotic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer.
    Yuh BE; Ruel NH; Mejia R; Wilson CM; Wilson TG
    Eur Urol; 2012 May; 61(5):1004-10. PubMed ID: 22366188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
    Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
    Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Algorithm for selecting men for pelvic lymph node dissection (PLND) during radical prostatectomy based on clinical risk factors in an Australian population.
    Sengupta S; Weerakoon M; Sethi K; Ischia J; Webb DR
    BJU Int; 2012 Apr; 109 Suppl 3():48-51. PubMed ID: 22458494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Undetectable PSA after radical prostatectomy is more likely in low burden N+ prostate cancer patients when an extended lymph node dissection is performed.
    Ramírez-Backhaus M; Mir Maresma MC; Mascarós JM; Bertolo R; Hernández J; Gómez Ferrer A; Casanova-Ramón Borja J; Domínguez Escrig JL; Collado-Serra A; Calatrava Fons A; Rubio-Briones J
    Actas Urol Esp (Engl Ed); 2019 Nov; 43(9):480-487. PubMed ID: 31174878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration.
    Bhindi B; Rangel LJ; Mason RJ; Gettman MT; Frank I; Kwon ED; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
    J Urol; 2017 Jul; 198(1):86-91. PubMed ID: 28130104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease.
    Badani KK; Reddy BN; Moskowitz EJ; Paulucci DJ; Beksac AT; Martini A; Whalen MJ; Skarecky DW; Huynh LM; Ahlering TE
    Urol Oncol; 2018 Jun; 36(6):310.e1-310.e6. PubMed ID: 29625782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.
    Mandel P; Rosenbaum C; Pompe RS; Steuber T; Salomon G; Chun FK; Graefen M; Huland H; Tilki D
    World J Urol; 2017 Dec; 35(12):1833-1839. PubMed ID: 28828530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radical prostatectomy for clinical T4 prostate cancer.
    Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
    Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.